Communication of the meeting of Transparency Council No. 46/2025 on 27 October 2025 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 46/2025 on 27 October 2025 during which the following resolutions were adopted:

1. At its meeting on 27 October 2025, the Transparency Council adopted position No. 148/2025 on the legitimacy of classifying the healthcare service “Optometrist consultation” as a guaranteed service
2. At its meeting on 27 October 2025, the Transparency Council adopted position No. 149/2025 on the evaluation of Columvi (glofitamabum) under the B.12.FM drug program. “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”
3. At its meeting on 27 October 2025, the Transparency Council adopted position No. 150/2025 on the evaluation of Legrex (ticagrelor) in combination with acetylsalicylic acid (ASA) for the prevention of cardiovascular events in adult patients with acute coronary syndrome (ACS)
4. At its meeting on 27 October 2025, the Transparency Council adopted position No. 151/2025 on the evaluation of Legrex (ticagrelorum) in the indication: in combination with acetylsalicylic acid (ASA) for the prevention of cardiovascular events in adult patients: with a history of myocardial infarction (heart attack) and a high risk of cardiovascular events
5. At its meeting on 27 October 2025, the Transparency Council adopted position No. 152/2025 on the evaluation of Itulazax (betula verrucosa) for the treatment of allergic rhinitis and/or conjunctivitis
6. At its meeting on 27 October 2025, the Transparency Council adopted position No. 153/2025 on the evaluation of Crysvita (burosumab) under drug program B.151 “Treatment of patients with X-linked hypophosphatemia (XLH) (ICD-10: E.83.3)”
7. At its meeting on 27 October 2025, the Transparency Council adopted position No. 154/2025 on the validity of issuing approvals for the reimbursement of the drug Ospolot (sultiam) for the following indications: epilepsy, drug-resistant epilepsy, drug-resistant epilepsy in the course of Rett syndrome
8. At its meeting on 27 October 2025, the Transparency Council adopted position No. 155/2025 on the legitimacy of issuing approvals for the reimbursement of the drug Inovelon (rufinamidum) for the following indications: drug-resistant epilepsy, Lennox-Gastaut syndrome
9. At its meeting on 27 October 2025, the Transparency Council adopted position No. 156/2025 on the validity of issuing approvals for the reimbursement of the drug Fycompa (perampanel) for the following indications: drug-resistant epilepsy, drug-resistant epilepsy with focal seizures

Transparency Council meeting protocol >>